Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 50, Issue 6, 2008, Pages 1181-1189

  Lock, Richard ^a   Carol, Hernan ^a   Houghton, Peter J ^b   Morton, Christopher L ^b   Anders Kolb, E ^c   Gorlick, Richard ^c   Patrick Reynolds, C ^d   Maris, John M ^e   Keir, Stephen T ^f   Wu, Jianrong ^b   Smith, Malcolm A ^g  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABT 263; Bcl 2; Developmental therapeutics; Preclinical testing

Indexed keywords

ABT 263; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR XENOGRAFT;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; FEMALE; HUMANS; MICE; MICE, INBRED STRAINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42349109916     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21433     Document Type: Article

References (31)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
2. Letai A, Bassik MC, Walensky LD, et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer cell 2002;2:183-192.
3. Kuwana T, Bouchier-Hayes L, Chipuk JE, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005;17:525-535.
4. Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer cell 2006;9:351-365.
5. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007;315:856-859.
6. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-1337.
7. Elmore SW. ABT-263: An orally bioavailable small molecule inhibitor of Bcl-2 family proteins. Eur J Cancer Suppl 2006;4:143.
8. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677-681.
9. Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2006.
10. Del Gaizo Moore V, Brown JR, Certo M, et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J clin Invest 2007;117: 112-121.
11. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer cell 2006; 10:389-399.
12. Lin X, Morgan-Lappe S, Huang X, et al. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X(L) inhibitor ABT-737. Oncogene 2006.
13. Keshelava N, Frgala T, Krejsa J, et al. DIMSCAN: A microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 2005; 110:139-153.
14. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2007.
15. Friedman HS, Colvin OM, Skapek SX, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988;48:4189-4195.
16. Graham C, Tucker C, Creech J, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 2006;12:223-234.
17. Peterson JK, Tucker C, Favours E, et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 2005;11:6950-6958.
18. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004;103:3905-3914.
19. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2006.
20. Bachmann PS, Gorman R, Mackenzie KL, et al. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. Blood 2005;105:2519-2526.
21. Robinson BW, Behling KC, Barrett JS, et al. Pre-clinical in vitro evaluation of BCL-2 antisense compound GenasenseTM (G3139; Genta, Inc.) as a targeted pro-apoptotic agent for leukemias with t(4;11)(q21;q23) translocations. Blood 2005;106: Abstr #3360.
22. Rege JM, Robinson BW, Gupta M, et al. Pan-BCL-2 family small molecule inhibitor GX 015-070(GeminX, Inc.) exhibits single agent cytotoxicity, is synergistic with select anti-leukemia cytotoxic agents, and induces apoptosis in cell lines with t(4;11)(q21;q23) translocations. Blood 2005; 106: Abstr #3368.
23. Planey SL, Abrams MT, Robertson NM, et al. Role of apical caspases and glucocorticoid-regulated genes in glucocorticoid-induced apoptosis of pre-B leukemic cells. Cancer Res 2003;63: 172-178.
24. Wang Z, Malone MH, He H, et al. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem 2003; 278:23861-23867.
25. Medh RD, Webb MS, Miller AL, et al. Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics 2003;81:543-555.
26. Abrams MT, Robertson NM, Yoon K, et al. Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J Biol Chem 2004;279:55809-55817.
27. Shinjyo T, Kuribara R, Inukai T, et al. Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol 2001;21:854-864.
28. Oliver PM, Wang M, Zhu Y, et al. Loss of Bim allows precursor B cell survival but not precursor B cell differentiation in the absence of interleukin 7. J Exp Med 2004;200:1179-1187.
29. Kuribara R, Honda H, Matsui H, et al. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 2004;24:6172-6183.
30. Elmore SW, Bauch J, Fryer RM, et al. Bcl-2 Family Protein Inhibitors Induce a Unique Thrombocytopenia In Vivo. Blood 2006;108: Abstr #4236.
31. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007; 14(5): 943-951.